Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Effects of tissue plasminogen activator administration on cholinergic and cognitive deficits in in a transgenic model of Alzheimer's disease-like amyloid pathology

EF 2013-14

Résumé
Alzheimer's disease is the most common form of dementia worldwide and affects over 500 000 Canadians today. Current treatments for Alzheimer's are not very effective. Unless new treatments are found, the number of AD sufferers in Canada is expected to steadily rise. One of the most important features of Alzheimer's is the deterioration of cells in a part of the brain called the basal forebrain cholinergic nuclei (BFCN); in Alzheimer's disease, these cells show more death and loss of synapses (structures that allow neurons to transmit signals) than other cells. These BFCN cells use a chemical messenger called acetylcholine which is associated with learning and memory, and damage to these cells is associated with the cognitive impairments seen in Alzheimer's. BFCN cells depend on a protein called Nerve Growth Factor (NGF) for survival and for the maintenance of their synapses. Research by the lab of Dr. Claudio Cuello at McGill has recently described how NGF is produced from pro-NGF by a protein called Plasmin, which is in turn produced by a protein called Tissue Plasminogen Activator (tPa). Dr. Cuello's lab has also shown that Plasmin and tPa levels are low in the brains of Alzheimer's patients, suggesting that the BFCN cell degradation in the brains of Alzheimer's sufferers may be caused by a reduction in NGF formation. Likewise, they showed that disruption of NGF formation in rats can lead to the kind of cognitive deficits and cell death that are seen in Alzheimer's disease. As such, increasing the amount of NGF in the BFCN might help to protect BFCN cells and thus help to mitigate the effects of Alzheimer's disease. Since tPa helps to produce Plasmin and Plasmin helps to produce NGF, we hypothesize that treatment with tPa should restore normal levels of NGF in the BFCN of rats that have been engineered to show symptoms of Alzheimer's disease. We also expect that this increase in NGF should stop brain cells in this area from decaying, and should stop cognitive deficits from developing. We will use a rat model of Alzheimer's that was recently produced by Dr. Cuello's lab, since it accurately mimics human Alzheimer's disease without many genetic changes. To test our hypotheses, we will use 16 Alzheimer-model rats and 16 normal rats from the same litters. At 13-15 months of age, half of these animals will begin to receive tPa directly into their brains for four weeks; the other group will receive cold saline for the same amount of time. We will have established the optimal dose of tPa from earlier pilot studies. During the last week, we will assess the cognitive abilities of the rats using a test of spatial memory and a test of association learning. On the last day of treatment, the animals will be sacrificed. One half of their brain will be used to assess levels of Plasmin, pro-NGF, and NGF. The other will be examined with a microscope to observe the extent of cell death and synapse loss in the BFCN cells. We expect that animals with increased tPa in the brain will show greater levels of plasmin and NGF, and lower levels of pro-NGF. We also expected that when the Alzheimer-model rats are given tPA, they will not show the cell death, synapse loss, and cognitive deficits that they usually exhibit. This study will investigate whether Tissue Plasminogen Activator can help mitigate Alzheimer's-like symptoms in a rat model of Alzheimer's disease. This study could suggest new treatments for Alzheimer's disease in humans.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311872
Name
Pentz Rowan D
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effects of tissue plasminogen activator administration on cholinergic and cognitive deficits in in a transgenic model of Alzheimer's disease-like amyloid pathology
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S; Basal Forebrain Cholinergic Nuclei; Cholinergic Synapses; Fear Conditioning; Immunohistochemistry; Morris Water Maze; Nerve Growth Factor; Tissue Plasminogen Activator; Transgenic; Western Blot
Abstract
Alzheimer's disease is the most common form of dementia worldwide and affects over 500 000 Canadians today. Current treatments for Alzheimer's are not very effective. Unless new treatments are found, the number of AD sufferers in Canada is expected to steadily rise. One of the most important features of Alzheimer's is the deterioration of cells in a part of the brain called the basal forebrain cholinergic nuclei (BFCN); in Alzheimer's disease, these cells show more death and loss of synapses (structures that allow neurons to transmit signals) than other cells. These BFCN cells use a chemical messenger called acetylcholine which is associated with learning and memory, and damage to these cells is associated with the cognitive impairments seen in Alzheimer's. BFCN cells depend on a protein called Nerve Growth Factor (NGF) for survival and for the maintenance of their synapses. Research by the lab of Dr. Claudio Cuello at McGill has recently described how NGF is produced from pro-NGF by a protein called Plasmin, which is in turn produced by a protein called Tissue Plasminogen Activator (tPa). Dr. Cuello's lab has also shown that Plasmin and tPa levels are low in the brains of Alzheimer's patients, suggesting that the BFCN cell degradation in the brains of Alzheimer's sufferers may be caused by a reduction in NGF formation. Likewise, they showed that disruption of NGF formation in rats can lead to the kind of cognitive deficits and cell death that are seen in Alzheimer's disease. As such, increasing the amount of NGF in the BFCN might help to protect BFCN cells and thus help to mitigate the effects of Alzheimer's disease. Since tPa helps to produce Plasmin and Plasmin helps to produce NGF, we hypothesize that treatment with tPa should restore normal levels of NGF in the BFCN of rats that have been engineered to show symptoms of Alzheimer's disease. We also expect that this increase in NGF should stop brain cells in this area from decaying, and should stop cognitive deficits from developing. We will use a rat model of Alzheimer's that was recently produced by Dr. Cuello's lab, since it accurately mimics human Alzheimer's disease without many genetic changes. To test our hypotheses, we will use 16 Alzheimer-model rats and 16 normal rats from the same litters. At 13-15 months of age, half of these animals will begin to receive tPa directly into their brains for four weeks; the other group will receive cold saline for the same amount of time. We will have established the optimal dose of tPa from earlier pilot studies. During the last week, we will assess the cognitive abilities of the rats using a test of spatial memory and a test of association learning. On the last day of treatment, the animals will be sacrificed. One half of their brain will be used to assess levels of Plasmin, pro-NGF, and NGF. The other will be examined with a microscope to observe the extent of cell death and synapse loss in the BFCN cells. We expect that animals with increased tPa in the brain will show greater levels of plasmin and NGF, and lower levels of pro-NGF. We also expected that when the Alzheimer-model rats are given tPA, they will not show the cell death, synapse loss, and cognitive deficits that they usually exhibit. This study will investigate whether Tissue Plasminogen Activator can help mitigate Alzheimer's-like symptoms in a rat model of Alzheimer's disease. This study could suggest new treatments for Alzheimer's disease in humans.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pentz, Rowan D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~